CHICAGO – (Nov. 26, 2018). Materialise NV (Nasdaq: MTLS), a world leading 3D printing solutions provider, is working with partners to remove uncertainty and confusion for hospitals and physicians who are incorporating 3D printing into their diagnostic and surgical planning processes.
Materialise has launched a certification program that allows printer manufacturers that partner with the company to have products tested and validated as being fully compatible with Materialise Mimics inPrint software. inPrint is the first and only software to gain clearance from the FDA to develop 3D printed anatomical models for diagnostic and surgical planning uses. The inPrint software is printer- and material-agnostic, allowing Materialise to develop partnerships and solutions to meet a range of hospital and clinician requirements.
Leuven, Belgium – June 19, 2018. Materialise NV (NASDAQ: MTLS) is a world leader in the development of technology enabling personalized healthcare solutions. Materialise’s latest patent, accepted by the Australian Patent Office, concerns Materialise’s 3D planning technologies and 3D-printed guides which enable the design of screw placements for the fit and fixation of customized implants. With the recent expansion of its portfolio of medical patents, Materialise continues to strengthen its unique position in the healthcare industry, supporting its commitment to help patients worldwide through technological innovation.
Leuven, Belgium – March 23, 2018. Materialise NV (Nasdaq: MTLS) is the first company in the world to receive FDA clearance for software intended for 3D printing anatomical models for diagnostic use. Leading hospitals are adopting integrated 3D printing services as part of their medical practices as they recognize the added value it brings to personalized patient care. Materialise brings nearly three decades of experience in developing medical solutions that help researchers, engineers and clinicians achieve the desired patient outcomes.
PLYMOUTH, Michigan – March 6, 2018. Materialise NV (Nasdaq: MTLS) launched a shoulder planner for surgeons with the possibility to plan shoulder arthroplasty cases and order patient-specific shoulder guides, in collaboration with DePuy Synthes. The TRUMATCH® Personalized Solutions Shoulder System, revealed at the AAOS Annual Meeting in New Orleans, marks a further extension of Materialise’s longstanding collaboration with DePuy Synthes, who will distribute the solution in the United States, Canada, Australia, New Zealand and Europe.